PGP and ovarian carcinoma: A further study strengthens the importance of testing this combination: Vaidyanathan et al. [61] tested ovarian cancer cell lines resistant to paclitaxel and olaparib for cross-resistance to other anti-cancer agents and for circumvention of resistance through inhibition of P-GP.